KB-1394

Panitumumab

Home » Antibody » Panitumumab

Background

Panitumumab, a monoclonal antibody of notable therapeutic significance, precisely targets the epidermal growth factor receptor (EGFR). Its sophisticated mechanism of action entails a specific binding affinity to the extracellular domain of EGFR, effectively impeding the receptor's activation and subsequent signaling cascade. This interference culminates in the curtailment of cell proliferation and survival, particularly within tumor cells expressing EGFR. Primarily harnessed for the treatment of metastatic colorectal cancer refractory to alternative chemotherapy regimens, panitumumab stands as a pivotal intervention in cases where other therapeutic avenues have proven ineffective.

Specifications

Catalog Number:
KB-1394
Cell Line Name:
Panitumumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
EGFR
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Easley C, Kirkpatrick P. FRESH FROM THE PIPELINE: Panitumumab. Nat Rev Drug Discov. 2006;5:987¨C8. 2. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714¨C27.
Please enable JavaScript in your browser to complete this form.